Aptevo Therapeutics Stock Forecast, Price & News

Aptevo Therapeutics (NASDAQ:APVO) Frequently Asked Questions

Is Aptevo Therapeutics a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aptevo Therapeutics stock.
View analyst ratings for Aptevo Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Aptevo Therapeutics?

Wall Street analysts have given Aptevo Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aptevo Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aptevo Therapeutics?

Aptevo Therapeutics saw a decrease in short interest in August. As of August 31st, there was short interest totaling 74,300 shares, a decrease of 20.8% from the August 15th total of 93,800 shares. Based on an average daily volume of 71,600 shares, the short-interest ratio is currently 1.0 days.
View Aptevo Therapeutics' Short Interest.

When is Aptevo Therapeutics' next earnings date?

Aptevo Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Aptevo Therapeutics.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) released its quarterly earnings results on Wednesday, August, 11th. The biotechnology company reported ($1.78) earnings per share for the quarter, beating the Zacks' consensus estimate of ($1.84) by $0.06. The biotechnology company earned $3.11 million during the quarter, compared to analysts' expectations of $2.70 million. Aptevo Therapeutics had a negative net margin of 309.94% and a negative trailing twelve-month return on equity of 276.54%.
View Aptevo Therapeutics' earnings history.

How has Aptevo Therapeutics' stock been impacted by COVID-19?

Aptevo Therapeutics' stock was trading at $0.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APVO shares have increased by 3,392.9% and is now trading at $14.67.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for APVO?

2 equities research analysts have issued 12 month price targets for Aptevo Therapeutics' stock. Their forecasts range from $50.00 to $50.00. On average, they expect Aptevo Therapeutics' share price to reach $50.00 in the next year. This suggests a possible upside of 240.8% from the stock's current price.
View analysts' price targets for Aptevo Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Aptevo Therapeutics' key executives?

Aptevo Therapeutics' management team includes the following people:

• Marvin L. White, President, Chief Executive Officer & Director
• Jeffrey G. Lamothe, Chief Financial Officer, Treasurer & Senior VP
• Scott C. Stromatt, Chief Medical Officer & SVP-Clinical Development
• SoYoung Kwon, SVP, General Counsel & Head-Corporate Affairs
• Elif McDonald, Senior Director-Investor Relations

Who are some of Aptevo Therapeutics' key competitors?

Some companies that are related to Aptevo Therapeutics include Athersys (ATHX), Millendo Therapeutics (MLND), NexImmune (NEXI), Harrow Health (HROW), Theratechnologies (THERF), CymaBay Therapeutics (CBAY), Syros Pharmaceuticals (SYRS), Sernova (SEOVF), Alpine Immune Sciences (ALPN), Sierra Oncology (SRRA), XOMA (XOMA), DURECT (DRRX), Checkpoint Therapeutics (CKPT), GX Acquisition (GXGX) and Angion Biomedica (ANGN).
View all of APVO's competitors.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

What is Aptevo Therapeutics' stock symbol?

Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO."

How do I buy shares of Aptevo Therapeutics?

Shares of APVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptevo Therapeutics' stock price today?

One share of APVO stock can currently be purchased for approximately $14.67.

How much money does Aptevo Therapeutics make?

Aptevo Therapeutics has a market capitalization of $71.79 million and generates $4.31 million in revenue each year.

How many employees does Aptevo Therapeutics have?

Aptevo Therapeutics employs 58 workers across the globe.

What is Aptevo Therapeutics' official website?

The official website for Aptevo Therapeutics is www.aptevotherapeutics.com.

Where are Aptevo Therapeutics' headquarters?

Aptevo Therapeutics is headquartered at 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121.

How can I contact Aptevo Therapeutics?

Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The biotechnology company can be reached via phone at (206) 838-0500 or via email at [email protected].